ZVRA Temel İstatistikler
YÜKSEK
9.99
Açık
9.53
Hacim
1.51M
Düşük
9.47
Önceki Kapanış
9.53
İşlem Değeri
14.76M
52H En Yüksek
15.04
Göreceli Hacim
0.961
Dalgalanma (%)
5.46%
52H En Düşük
7.16
Devir Oranı
2.57%
Piyasa Değeri
563.07M
F/K (TTM)
4.42
F/K (Yıllık)
6.807
GD/DD
2.74
F/S
4.61
Hisse Başına Kazanç (EPS)
2.154
Temettü (TTM)
0
Temettü Verimi
0.00%
Dolaşımdaki hisseler
59.11M
Para Birimi
USD
ZVRA Fiyat Performansı
7 gün
30 gün
90 gün
180 gün
Yıl başından bugüne
1 Yıl
ZVRA Para Akışı Dağılımı
ZVRA Günlük Açığa Satış Hacmi
ZVRA Short Interest Geçmişi
ZVRA Hisse Özeti
As of 2026-07-27, the Zevra Therapeutics, Inc. (ZVRA) stock price today is 9.71. Based on this price, the company has a market capitalization of $563.07M, with a P/E ratio of 4.42.
On 2026-07-27, ZVRA traded between 9.47 and 9.99. Today’s stock price is 2.53% above the daily low and 2.80% below the daily high, placing ZVRA orta seviyesine yakın its most recent trading range.
Trading volume currently stands at 1.51M, compared with an average daily volume of 1.58M. This suggests that trading activity is olağan seviyesiyle kabaca uyumlu than usual.
Over the past year, Zevra Therapeutics, Inc. shares have traded between 7.16 and 15.04. At today’s price, ZVRA is 35.61% above its 52-week low and 35.44% below its 52-week high.
ZVRA İlgili haberler
Hakkında ZVRA
Şirket adı
Zevra Therapeutics, Inc.
Sektör
Health Technology
Endüstri
Pharmaceuticals: Major
Borsalar
Nasdaq
Çalışan Sayısı
61
Lot Büyüklüğü
100
Resmî web sitesi
Para Birimi
USD
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Related Stocks
ZVRA FAQ
© 2026 CoinGlass, all rights reserved
